Latest
industry research report on: Global Choroidal NeoVascularization
Market : Industry Size, Share, Research, Reviews, Analysis,
Strategies, Demand, Growth, Segmentation, Parameters, Forecasts
Choroid is the part of eye that
lies in between the retina (vision sensory area) and the sclera (the
outer layer of the eye), this area consist of blood vessels that
supply nutrients to the retinal part of our eye. Choroidal
NeoVascularization (CNV)
is a disease, which is characterized by the formation of new blood
vessels that arise either due to the presence of Vascular Endothelial
Growth Factors (VGEF) or due to Age-related Macular Degeneration
(AMD). This results in fluid accumulation below the retinal pigment
epithelium, which can lead to vision loss or extreme myopic vision
among individuals. CNV is also seen in individuals with diabetic
retinopathy. In rare cases, it can occur among individuals with
defects in Bruch's membrane, the innermost layer of the choroid. It
has also been observed by the American Academy of Ophthalmology and
other reports that patients with CNV in one eye have a very high
probability to contract CNV in the other eye within a short frame of
time. According to the British Journal of Ophthalmology published in
2007, age?related macular degeneration (AMD) is one of the leading
causes of irreversible sight loss among adults registered as legally
blind. Among these, two-thirds of people with AMD have the wet form,
which can progress quickly causing irreversible sight loss within
days or weeks. In 2007, approximately 250,000 people were suffering
from neovascular AMD in the U.K, with an incidence rate of 25,000 and
30,000 new cases annually.
The
only successful treatment option that is available commercially in
the market for CNVs include intravitreal (direct to the eye)
injections of anti-VEGF drugs to control the neovascularization and
reduce the fluid accumulated. The most common anti-VGEF compounds are
Ranibizumab (Trade name: Lucentis), Bevacizumab (Trade name: Avastin)
and the novel drug Pegaptanib (Trade name: Macugen). These drugs
belong to a class called anti-angiogenic drugs, their primary
objective being the inhibition of the growth of new blood vessels.
Anti angiogenic drugs are more commonly used for cancer treatment,
where cancerous cells promote angiogenesis resulting in the
proliferation of cells in large numbers, thus forming tumors.
Bevacizumab is a successfully used cost effective drug for the
treatment of cancer as well as AMD related CNVs with a very high half
life (more than twice) in comparison with Ranibizumab. However
chances of adverse effects with Bevacizumab are comparatively higher,
hence Ranibizumab (Lucentis) is now currently the most effectively
and safely used treatment for CNV. Pegaptanib on the other hand is in
Phase IV of the clinical trials wherein only 1000 patients so far
have been treated with significant success rate.
With
increasing aging population throughout the world the probability of
occurrence of wet-AMD is high, especially in China and Japan where
the aging population is predicted to tip over the young adult
population. The patents for both Bevacizumab and Ranibizumab are till
2018 hence after patent expiry it is predicted that their sales shall
significantly increase, especially with the entrance of Asian drug
manufacturers.
Have Any Query? Ask Our Expert @
https://www.marketresearchreports.biz/sample/enquiryBuy/1352318
Currently the companies that
manufacture Ranibizumab are Novartis (licensed) in global market and
Genetech (patented) in the U.S. Bevacizumab too was developed by
Roche Pharma in association with Genentech and is currently marketed
by Roche internationally. Pegaptanib is manufactured by Eyetch Inc.
and marketed by Pfizer Inc.
Pegaptanib has been approved
and is available only in North America, Europe, Brazil and Australia.
Ranibizumab is available under the name Lucentis with high market
share in Europe and North America and growing in Asia-Pacific region.
Bevacizumab is sold as Avastin globally with highest growth rate
observed in Asia and highest voluminous growth seen in the North
Americas and European markets.
This research report analyzes
this market on the basis of its market segments, major geographies,
and current market trends. This report provides comprehensive
analysis of
Market growth drivers
Factors limiting market
growth
Current market trends
Market structure
Market projections for
upcoming years
This report is a complete study
of current trends in the market, industry growth drivers, and
restraints. It provides market projections for the coming years. It
includes analysis of recent developments in technology, Porter’s
five force model analysis and detailed profiles of top industry
players. The report also includes a review of micro and macro factors
essential for the existing market players and new entrants along with
detailed value chain analysis.
Reasons for Buying this
Report
This report provides
pin-point analysis for changing competitive dynamics
It provides a forward
looking perspective on different factors driving or restraining
market growth
It provides a six-year
forecast assessed on the basis of how the market is predicted to grow
It helps in understanding
the key product segments and their future
It provides pin point
analysis of changing competition dynamics and keeps you ahead of
competitors
It helps in making informed
business decisions by having complete insights of market and by
making in-depth analysis of market segments
It provides distinctive
graphics and exemplified SWOT analysis of major market segments
About
us
MarketResearchReports.biz
is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Contact
Mr.
Nachiket
State
Tower
90
Sate Street, Suite 700
Albany,
NY 12207
Tel:
+1-518-621-2074
No comments:
Post a Comment